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analysis is made in the societal cost perspective, adding direct
medical costs charged both on the National Health Service and
the patient, since orlistat is not reimbursed. Costs and health
beneﬁts are discounted at a 3.5% annual rate. RESULTS: The
treatment with orlistat of the Italian obese population (estimated
in more than 4 million subjects), produces an estimated average
increase in quality-adjusted life expectance of 0.05 (0.035–
0.065) QALY/patient, an estimated reduction of cardiovascular
events and diabetes onsets at an estimated overall increased cost
(based on the current orlistat public price) of about 12 (1.7–13.7)
million Euro in 10 years. On the Impaired Glucose Tolerance
(IGT) patients subgroup (283,000 people), the beneﬁts are rela-
tively larger, and they come at an increased cost of 608 (-1.6–
918) thousands Euro. Estimated average (95% CI) cost-utility
incremental ratios are 60.8 (9.2–84.5) and 16.34 (-43.5–27.54)
thousand Euro/QALY for the whole cohort and the IGT sub-
population, respectively. CONCLUSION: Orlistat shows a good
pharmacoeconomic proﬁle, especially in IGT patients, with a
cost-utility of 16.340 Euro/QALY. This value is lower than that
of several therapeutic strategies commonly accepted in developed
countries.
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OBJECTIVES: Obesity, hypertension and dyslipidemia (low
HDL-cholesterol, high triglycerides) are known risk factors (RF)
for the development of cardiovascular diseases and diabetes mel-
litus type 2 (DM). The aim of the study was to develop a decision
analytic model as a tool to assess the cost-effectiveness of
treatment options of obesity and associated cardiovascular risk
factors. METHODS: As part of the German Metabolic and
Cardiovascular Risk Project GEMCAS a decision analytic model
from the German payer’s perspective was developed. RESULTS:
The model has a cycle length of one year and consists of nine
health states (HS): (HS1) DM without complications and no
further RF; (HS2) DM without complications and one further RF
(HS3) DM without complications and 2–4 further RF (HS4) DM
with microvascular complications (HS5) DM with macrovascu-
lar complications (HS6) healthy (HS7) 1–4 RF (HS8) post myo-
cardial infarction or stroke (HS9) death. Annual costs have been
assessed for each health state as well as for transitions due to
myocardial infarction or stroke: (HS1) 626 Euro (HS2) 794 Euro
(HS3) 962 Euro (HS4) 6.276 Euro (HS5) 3.633 Euro (HS6), 0
Euro (HS7), 336 Euro (HS8) 1.710 Euro, transition costs for
myocardial infarction are 4.560 Euro and for stroke 4.780 Euro.
Target population has a deﬁned risk proﬁle and transition prob-
abilities are calculated using the Framingham Risk Equation for
myocardial infarction and stroke. Additionally an independent
effect of obesity according to the INTERHEART study was
assumed. The development of DM was calculated based on the
risk equation from San Antonio Heart Study. CONCLUSION:
The presented model is a valuable tool to assess the cost-
effectiveness of different treatments options and can be adopted
for new interventions easily.
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OBJECTIVES: Given the increasing frequency of obesity and the
costs associated with it, it is vital to determine which interven-
tions are effective and cost-effective versus the alternatives. A
crucial step in both cases is a critical appraisal of the literature.
This study examined the quality of economic evaluations (EE)
of obesity interventions using a quantitative approach.
METHODS: Economic evaluations were selected using the NHS
Economic Evaluations Database (NHS EED, York UK)(1995–
2006). Quality was based on the method by Chiou (2003)
because its development involved many health economists and it
provides an overall quality score (range: -1100) using 16 criteria.
Associations between study characteristics and quality were
examined using regression analysis. Characteristics included
publication year, type of intervention (including diet, behaviour,
medicine, surgery, combined intervention), source of effective-
ness data (single study, literature review), country of evaluation,
and source of funding. RESULTS: Thirty-four EEs were identi-
ﬁed and all of them fulﬁlled only some criteria. The most
common weaknesses were no discussion of potential biases and
inappropriate time horizon or discounting method. Mean overall
score was 52 (range: 24–76, SD: 13). Recent EEs were better than
older ones (+1.5 points/year) and European EEs were better (15
points) than non-European ones. Source of effectiveness data and
source of funding were not associated with quality after adjust-
ment for year and country. Type of intervention was never asso-
ciated with quality. CONCLUSION: The average quality of EEs
seems moderate given a score of 52/100. There is much room for
improvement and examination of individual criteria is indispens-
able in achieving this. Determination of overall quality scores is
not an adequate substitute for a critical appraisal. Sometimes a
single weakness in a “very good” EE can be fatal and render
cost-effectiveness estimates useless. In contrast, elements of
a “poor” EE can be valuable when determining the cost-
effectiveness of an intervention.
PAIN—Clinical Outcomes Studies
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OBJECTIVES: Despite being a common problem, there is no
published epidemiological data on pain in Turkey. This large scale
survey had the main objective of demonstrating the incidence of
acute pain, but also sought to explore how individuals perceive
their pain, the impact it had on their lives, their perception of the
attitudes of others towards their pain, treatments received and the
adequacy of treatment. METHODS: Screening interviews identi-
ﬁed respondents aged 18 years with acute pain, for in-depth
interviews. It addressed the following aims: a) estimating the
incidence of acute pain in Turkey; b) quantifying causes of acute
pain; c) exploring the demographics of acute pain; d) exploring the
impact of acute pain on individual’s quality of life and daily
activities e) understanding current treatment practices.RESULTS:
Six percent of the respondents had acute pain. Sixty-seven percent
of the 313 respondents willing to participate, had pain due to
another disease, 33% of them did not have any disease related to
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their pain. Their pain intensity during last episode of painwas 5 on
a 10-point Numeric Rating Scale (NRS). 39% of the respondents
had moderate pain (NRS = 5–7), 43% had severe pain (NRS = 7),
67% had headaches, 22% had back pain. 96% of the acute pain
sufferers were using drugs for last three months. 96% of them
were taking Aspirin® (acetyl salicilic acid), 91% Vermidon®
(paracetamol), 90% Novalgin® (Dipyrone), and 80% Apranax®
(naproxen sodium). CONCLUSION: Six percent of Turkish
adults had acute pain. Sixty-seven percent of the respondents who
had acute pain had accompying disease causing the pain. Pain is a
major health care problem in Turkey that needs to be evaluated
and researched in depth.
PAIN—Cost Studies
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OBJECTIVES: There are two forms of injectable IV diclofenac
available (Dyloject bolus and Voltarol infusion). We conducted a
cost minimization analysis to determine the total cost of each
treatment strategy. METHODS: A decision-analytic model was
developed to estimate total treatment costs of IV bolus versus IV
infusion diclofenac. The modeled population was patients who
post-operatively would require injectable NSAIDs to control their
pain. The model timeframe was for the duration that a patient
required post-operative pain management with injectable medi-
cation. The model inputs included the actual/estimated cost of
medicines, the cost of the IV administration process (staff time and
consumables), and the cost of treating adverse events (staff time,
medicines and consumables). The unit costs and resources are
based on UK data. The results are expressed as Pounds Sterling
and as average cost per patient. One-way sensitivity analyses were
also conducted on key parameters. RESULTS: The total cost of
treating post-operative pain was less with IV bolus diclofenac
(Dyloject) than with IV infusion diclofenac (Voltarol). Diclofenac
IV bolus cost a mean27.84 per patient overall versus diclofenac
IV infusion mean cost of 78.61 per patient. The difference in
overall cost is attributable to the cost ofNSAIDs (IV bolus12.19
versus 1.69 IV Infusion), the cost of administering the NSAID
(IV bolus 9.72 versus 49.73 IV Infusion) and the cost of
consumables (IV bolus 1.40 versus 16.72 IV infusion). The
difference in the costs of rescuemedication (IV bolus2.48 versus
6.14 IV infusion) and of treating adverse events (IV bolus
2.061 versus 4.33 IV infusion) was less. One-way sensitivity
analyses show the results are sensitive to the cost of staff time and
consumables. CONCLUSION: Diclofenac IV bolus (Dyloject) is
cost saving relative to diclofenac IV infusion (Voltarol) in the
treatment of post-operative pain.
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OBJECTIVES: To develop an expected-cost model to examine
the impact of opioid rotation among patients with chronic non-
cancer pain from the payor perspective METHODS: A decision
tree was developed depicting pathways a patient may follow over
the course of 1 year while taking long acting opioids. Up to 2
switches and 5 dose adjustments were possible for each of the
three treatment arms: 1) MS Contin ER switch to OPANA ER; 2)
MS Contin ER switch to OxyContin ER; and 3) OPANA ER
switch to OxyContin ER for patients where morphine is not an
appropriate ﬁrst line treatment option. Cost data included drug
acquisition costs for extended release (ER) and immediate release
(IR) opioids, physician contact reimbursement for pain special-
ists and primary care physicians. Estimated rates for side effects
were assumed similar for the most frequently reported side effects
(constipation, nausea, somnolence and sedation) and were
applied to all treatment arms. RESULTS: A total of 149 possible
pathways of care were evaluated among the 3 treatment arms.
Assuming a BID regimen, expected-cost range for treatments 1,
2, and 3 were: $3426–$4299, $3829–$5073, and $4556–$5098,
respectively. IR cost contribution of the total expected-cost for
treatment arms 1, 2, and 3 amounted to 17%, 21% and 24%,
respectively, and was dependent on the total daily ER dose.
CONCLUSION: Opioid rotation is thought to be the result of
the need to switch opioids when a therapy is not well tolerated by
the patient. Having an effective alternative for rotation/switching
if ﬁrst line treatment fails has the potential to reduce incremental
down stream costs by decreasing physician contacts due to dose
adjustment or the need for further switching. Furthermore, the
lack of effective pain management combined with non-tolerated
side effects may also require the need for additional medications
for pain (IR) and side effects.
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OBJECTIVES: To analyze health and non-health resources utili-
zation and derived costs of treating treating refractory painful
Radiculopathy followed in PCS under routine medical practice.
METHODS: A 12-weeks cross-sectional and retrospective analy-
sis was carried out in year 2006 in a whole-nation representative
sample of PC centres. Men and women above 18 years, with
chronic pain (6-month or more) due to cervical (17%) or lumbar
(83%) radiculopathy, refractory to, at least, one previous anal-
gesic were included in the analysis. Health resources included
all-type medical visits, hospitalizations, complementary test and
pharmacological and non-pharmacological therapies. Non-
health included wages loses due to loss-work-days equivalents
(LWDE = absenteeism days + days working with reduced pro-
ductivity due to pain). Pain severity was measured by McGill-
pain scale. RESULTS: One-thousand-four-hundred-ﬁfty-two
subjects [55.8% women, 56.7 (12.5) years] with cervical or
lumbar radiculopathy were analyzed. Last-week mean pain
severity was 71.4 (15.1) mm with 61.4% declaring the pain as
severe or worst the day of collecting data. Previous mean (SD)
number of drugs was 2.6 (1.4), with a 24.0% on one-drug only;
81% on NSAIDs, 47% on paracetamol, 32% on opiods, 17% on
muscle-relaxants, 9% on antiepileptics, and 7% on antidepres-
sants. Quarterly mean LWDE was 41.1 (28.6) days. Medical
visits average per trimester was 9.1 (6.2), with 3.9% declaring
one-hospitalization. Quarterly total mean cost was €2970
(2114); €1032 (1207) direct health cost and €1938 (1490) indi-
rect cost. CONCLUSION: In the primary care setting, health and
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